Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer
Author:
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2008.07873.x/fullpdf
Reference22 articles.
1. The association between measures of progression and survival in castrate-metastatic prostate cancer;Scher;Clin Cancer Res,2007
2. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer;Oudard;J Clin Oncol,2005
3. Is disease flare a problem?;Mahler;Cancer,1993
4. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer - a pilot study;Sugiono;Prostate Cancer Prostatic Dis,2005
5. Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC): delayed response and flare phenomenon should be considered;Fossa;Scand J Urol Nephrol,2002
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel;Journal of Urologic Oncology;2023-11-30
2. Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer;Journal of Clinical Medicine;2023-08-28
3. Assessment of oligometastasis status of prostate cancer following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone using PSA percentage decline rate;Frontiers in Endocrinology;2023-02-09
4. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease;Scandinavian Journal of Urology;2022-07-04
5. ‘FLARE’ of tumor marker in advanced gastric cancer treated with first-line systemic therapy;Therapeutic Advances in Gastroenterology;2022-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3